Safety analysis
ADVERSE EVENTS, ADVERSE EFFECTS, ADVERSE EVENT
Safety analyses were performed in 84 and 74 patients in sitagliptin and control groups, respectively (Fig. Clinical adverse effects during treatment.Adverse events were analyzed in all patients according to the actual use of sitagliptin. Clinical adverse events were assessed in 84 patients treated with sitagliptin and 74 patients treated without, for whom information on adverse effects was available. Laboratory adverse effects by follow-up point.*Between-group differences were based on Fisher’s exact test. 